What is MyndTec?
MyndTec Inc. operates at the intersection of neurology and medical engineering, specializing in the development of non-invasive therapeutic devices. Its flagship product, MyndMove, leverages functional electrical stimulation to facilitate neuroplasticity, effectively assisting patients recovering from stroke or spinal cord injuries. By focusing on the restoration of upper-limb function, the company addresses a critical gap in rehabilitation medicine. MyndTec's market position is defined by its commitment to evidence-based clinical outcomes, aiming to maximize patient independence through advanced neural pathway stimulation. As a privately held entity, the firm maintains a rigorous focus on commercializing technology that bridges the gap between clinical research and practical, life-enhancing patient care.
How much funding has MyndTec raised?
MyndTec has raised a total of $408K across 5 funding rounds:
Multiple Rounds
$313K
Stock/Share Issuance
$95K
Stock/Share Issuance (2025): $100K, investors not publicly disclosed
Stock/Share Issuance (2025): $100K, investors not publicly disclosed
Stock/Share Issuance (2025): $75K, investors not publicly disclosed
Stock/Share Issuance (2025): $38K, investors not publicly disclosed
Stock/Share Issuance (2026): $95K, investors not publicly disclosed
Key Investors in MyndTec
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for MyndTec?
With the recent injection of capital, MyndTec is poised to enter a phase of aggressive market penetration and operational scaling. The strategic roadmap likely involves expanding the clinical reach of the MyndMove platform, potentially targeting broader international markets and diversifying its therapeutic portfolio. By leveraging this late-stage financing, the company is well-positioned to enhance its manufacturing capabilities and invest in longitudinal clinical studies to further validate its neuro-rehabilitation efficacy. Investors and stakeholders will be monitoring the firm's ability to translate this financial backing into sustained revenue growth and increased adoption within rehabilitation centers globally, solidifying its status as a leader in the medical device industry.
See full MyndTec company page
